Clinical trials: Apixaban, completed
Ischemic Stroke, Stroke, Acute
Monitoring of NOAC Therapy: Standardizing Reference Intervals
This study is aimed to establish reference intervals of NOAC (dabigatran, apixaban and rivaroxaban) in ethnic Chinese patients.
- Conditions
- Ischemic Stroke, Stroke, Acute, Stroke Syndrome, Ischemic
- Trial name
- NCT04611893
- Where
- Hong Kong
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Atrial Fibrillation
Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT04593030
- Testing
- Warfarin, Apixaban
- Where
- United States
- Volunteers
- 220,518 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Pancreas Cancer, DVT
Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy
Study investigators will examine the absorption characteristics of apixaban, a direct-acting oral anticoagulation, in patients who have underwent a particular kind of surgery (pancreaticoduodenectomy) which involves resection of…
- Conditions
- Pancreas Cancer, DVT, Pulmonary Embolism
- Trial name
- PAP-UP (NCT04191928)
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Thomas Jefferson University
Atrial Fibrillation
Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S
The overall objective of this proposal is to execute a real-world database analysis to evaluate hospital readmissions among hospitalized nonvalvular atrial fibrillation (NVAF) patients in the U.S.
- Trial name
- NCT02769078
- Testing
- dabigatran, rivaroxaban, apixaban
- Volunteers
- 14,201 people
- Sponsor
- Bristol-Myers Squibb
Chronic Renal Insufficiency, Peritoneal Dialysis
Apixaban in Subjects With Peritoneal Dialysis
The primary objective of this study is to assess the pharmacokinetics of a single oral dose of apixaban (5mg) in participants with dialysis peritoneal versus participants with normal renal function.
- Trial name
- ApiDP (NCT04006093)
- Testing
- Apixaban single dose 5mg
- Where
- France
- Volunteers
- 24 people
- Sponsor
- University Hospital, Caen
Congenital Heart Disease, Atrial Arrhythmia
Apixaban in Adults With Congenital Heart Disease and Atrial Arrhythmias: the PROTECT-AR Study
The purpose of this study is to evaluate the safety and efficacy of apixaban for the prevention of thromboembolism in adult patients with congenital heart disease (CHD) and non-valvular atrial arrhythmias (AA)
- Conditions
- Congenital Heart Disease, Atrial Arrhythmia, Thromboembolism, Anticoagulants Causing Adverse Effects in Therapeutic Use
- Trial name
- PROTECT_AR (NCT03854149)
- Where
- 4 sites in Greece
- Volunteers
- 218 people
- Sponsor
- AHEPA University Hospital
Random Allocation, Intermittent Fasting
Pivotal BE Study of TAH3311 ODF vs ELIQUIS® Tablet Under Fasted Condition in Healthy Volunteers
This single-dose, open-label, randomized, four-way crossover study evaluates the pharmacokinetics, safety, and tolerability of TAH3311 5 mg in healthy volunteers under fasted and fed conditions.
- Conditions
- Random Allocation, Intermittent Fasting, Enteral Feeding
- Trial name
- NCT06689436
- Testing
- 5 mg Apixaban Oral Dissolving Film (fasting), 5 mg Apixaban Oral Dissolving Film (fed), 5 mg Apixaban Oral Tablet (US RS/RLD)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- TAHO Pharmaceuticals Ltd.
Atrial Fibrillation
A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation
To assess the effect of two doses of Apixaban (2.5 mg BID and 5 mg BID) versus Warfarin on the composite endpoint of major and clinically relevant non-major bleeding during the treatment period.
- Trial name
- NCT00787150
- Testing
- Apixaban, Warfarin sodium
- Where
- 18 sites in Japan
- Volunteers
- 222 people
- Sponsor
- Pfizer
NonValvular Atrial Fibrillation
Eliquis Regulatory Post Marketing Surveillance
The primary objective of this study is to examine the safety profile of Eliquis in Korean nonvalvular atrial fibrillation patients.
- Trial name
- NCT01885598
- Testing
- Apixaban
- Where
- South Korea
- Volunteers
- 3,335 people
- Sponsor
- Bristol-Myers Squibb
Short Bowel Syndrome, Anticoagulation
Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition
Short bowel syndrome (SBS) is defined as a loss of function of the small intestine resulting in a malabsorptive disorder. In SBS, oral drug absorption may be altered due to extensive intestinal resection.
- Trial name
- ABSORB (NCT04344717)
- Testing
- Apixaban single dose, Apixaban steady-state
- Where
- Belgium
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Atrial Fibrillation
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
The study goal is to determine the clinical benefit of percutaneous catheter-based left atrial appendage (LAA) closure in patients with non-valvular atrial fibrillation (NVAF) at high risk of stroke (CHA2DS2-VASc Score ≥2) as…
- Trial name
- CLOSURE-AF (NCT03463317)
- Testing
- CE-mark approved LAA closure devices, Acetylsalicylic acid, Clopidogrel
- Where
- 42 sites in Germany
- Volunteers
- 912 people
- Sponsor
- Charite University, Berlin, Germany
Venous Thromboembolism
Eliquis Regulatory Post Marketing Surveillance (rPMS)
The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the clinical usefulness of Eliquis through collecting, reviewing, identifying and verifying the safety and effectiveness information about…
- Trial name
- NCT01885585
- Testing
- Apixaban
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Bristol-Myers Squibb
Diabetes
ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)
Diabetic and nondiabetic patients will be evaluated if they had a first diagnosis of non-valvular atrial fibrillation and in therapy with non-vitamin K oral anticoagulants and with vitamin K oral anticoagulants.
- Trial name
- ORGANON (NCT02935855)
- Testing
- Dabigatran, Apixaban, Rivaroxaban
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University of Pavia
Healthy Volunteers
Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects
The purpose of this study is to assess the oral bioavailability of Apixaban solution formulation (Treatment B, 10 mg as 25 mL x 0.4 mg/mL) relative to Apixaban tablets (Treatment A, 10 mg as 2 x 5 mg tablets) in healthy subjects.
- Trial name
- NCT02034565
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Covid19
COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis
A multicenter, adaptive, randomized platform trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge
- Trial name
- NCT04650087
- Testing
- Apixaban 2.5 MG
- Where
- 121 sites in United States
- Volunteers
- 1,291 people
- Sponsor
- Thomas L. Ortel
Cirrhosis, Splenectomy
Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection
The purpose of this study is to determine whether Apixaban is effective and safe in Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients after Laparoscopic Splenectomy and Azygoportal Disconnection
- Conditions
- Cirrhosis, Splenectomy, Venous Thrombosis, Hypertension, Portal
- Trial name
- ESAPT (NCT05304455)
- Testing
- Apixaban 2.5 MG, Dipyridamole 25Mg Tab, subcutaneous Low Molecular Weight Heparin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Northern Jiangsu People's Hospital
Atrial Fibrillation Patients With Intermediate Stroke Risk
The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)
Atrial fibrillation (AF) increases the risk of stroke, and oral anticoagulation is strongly recommended for patients at high thromboembolic risk.
- Trial name
- NCT04437654
- Testing
- Anticoagulation group(DOAC group)
- Where
- South Korea
- Volunteers
- 1,803 people
- Sponsor
- Yonsei University
Coronary Artery Bypass Grafting, Postoperative Atrial Fibrilation
Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation
In this open-label, prospective, randomized pilot study, patients who develop atrial fibrillation after isolated coronary artery bypass grafting surgery will be identified.
- Conditions
- Coronary Artery Bypass Grafting, Postoperative Atrial Fibrilation, Stroke, Systemic Embolism
- Trial name
- NCT02889562
- Testing
- Apixaban, Warfarin
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Sanford Health
Uterine Hemorrhage
A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants
The purpose of this study is assess the: (a) incidence of severe uterine bleeding (SUB) following exposure to individual direct oral anticoagulant (DOACs) (rivaroxaban, apixaban, dabigatran) and warfarin, (b) individual DOACs…
- Trial name
- NCT04394234
- Testing
- Direct oral anticoagulant (DOACs), Warfarin
- Where
- United States
- Volunteers
- 961,985 people
- Sponsor
- Janssen Research & Development, LLC
Heart Failure
Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices
Prospective, randomized, controlled, open label, trial of LVAD patients with 1:1 randomization to either apixaban or warfarin.
- Trial name
- DOAC LVAD (NCT04865978)
- Testing
- Apixaban, Warfarin, LVAD implant
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Palak Shah